Monitor for future data readouts from this real-world study which could support expanded clinical adoption and potentially influence payer coverage decisions for PEDMARK in AYA and adult populations, representing a key growth opportunity beyond its current pediatric indication.
Price Chart
Executive Summary
Fennec Pharmaceuticals announced a clinical research collaboration with Tampa General Hospital Cancer Institute to evaluate the real-world clinical utility of PEDMARK in reducing cisplatin-induced ototoxicity in adolescent, young adult, and adult cancer patients. The study aims to generate real-world evidence to support broader clinical adoption of PEDMARK beyond its current pediatric approval.
Key Facts
- Tampa General Hospital Cancer Institute is initiating a real-world study of PEDMARK's effectiveness in reducing ototoxicity in AYA and adult patients receiving cisplatin chemotherapy
- PEDMARK is currently FDA-approved only for pediatric patients with localized non-metastatic solid tumors
- The study is observational and will evaluate clinical data and audiology monitoring in real-world settings
- PEDMARK has a 2A recommendation from NCCN for use in AYA patients
- The collaboration involves Tampa General Hospital and USF Health Morsani College of Medicine
Financial Impact
No immediate financial impact disclosed; potential long-term commercial expansion if study supports off-label use in AYA/adult populations
Risk Factors
- Study results may not demonstrate sufficient effectiveness in AYA/adult populations to drive meaningful adoption
- Real-world evidence may not be sufficient to support label expansion without additional clinical trials
- Commercial success depends on physician adoption and payer reimbursement for off-label use
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-023484 |
| Document: fencf-20260304x8k.htm | 0001104659-26-023484 |
| Document: 0001104659-26-023484-index-headers.html | 0001104659-26-023484 |
| Document: 0001104659-26-023484-index.html | 0001104659-26-023484 |
| Document: 0001104659-26-023484.txt | 0001104659-26-023484 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 19, 2026 7d ago | SC 13G/A | $10.27 | awaiting T+60 | — | $10.15 (−1.17%) |
Aug 31, 2026 7w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 31, 2026 7w ago | Insider Cluster | $12.03 | awaiting T+60 | — | $10.15 (−15.63%) |
Aug 11, 2026 10w ago | Press Release | $12.78 | awaiting T+60 | — | $10.15 (−20.58%) |
Jun 15, 2026 19w ago | Press Release | $9.19 $11.65 | ▲ +26.77% | ▲ +25.77% | $10.15 (+10.45%) |
May 22, 2026 22w ago | 8-K | $9.89 $11.87 | ▲ +20.02% | ▲ +17.30% | $10.15 (+2.63%) |
May 18, 2026 22w ago | 8-K | $9.76 $12.06 | ▲ +23.57% | ▲ +17.28% | $10.15 (+4.00%) |
May 14, 2026 23w ago | Press Release | $9.24 $10.94 | ▲ +18.40% | ▲ +14.81% | $10.15 (+9.85%) |
May 7, 2026 24w ago | Press Release | $6.90 $9.59 | ▲ +38.99% | ▲ +35.15% | $10.15 (+47.10%) |
Apr 28, 2026 25w ago | 8-K | $6.26 $9.99 | ▲ +59.58% | ▲ +55.47% | $10.15 (+62.14%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers